par Marechal, Raphaël ;De Schutter, Jef;Nagy, Nathalie ;Demetter, Pieter ;Lemmers, Arnaud ;Devière, Jacques ;Salmon, Isabelle ;Tejpar, Sabine;Van Laethem, Jean-Luc
Référence BMC cancer, 10, page (340)
Publication Publié, 2010
Référence BMC cancer, 10, page (340)
Publication Publié, 2010
Article révisé par les pairs
Résumé : | Activity of cetuximab, a chimeric monoclonal antibody targeting the epidermal growth factor receptor, is largely attributed to its direct antiproliferative and proapoptotic effects. Antibody-dependent cell-mediated cytotoxicity (ADCC) could be another possible mechanism of cetuximab antitumor effects and its specific contribution on the clinical activity of cetuximab is unknown. |